<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">RUDN Journal of Medicine</journal-id><journal-title-group><journal-title xml:lang="en">RUDN Journal of Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российского университета дружбы народов. Серия: Медицина</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-0245</issn><issn publication-format="electronic">2313-0261</issn><publisher><publisher-name xml:lang="en">Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">22796</article-id><article-id pub-id-type="doi">10.22363/2313-0245-2019-23-4-364-372</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ONCOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОНКОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Immunohistochemical Study of Tumor Cells Proliferative Activity at Different Graduations of Prostate Cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Иммуногистохимическое исследование пролиферативной активности опухолевых клеток при различных градациях аденокарциномы предстательной железы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kudryavtsev</surname><given-names>G. Y.</given-names></name><name xml:lang="ru"><surname>Кудрявцев</surname><given-names>Г. Ю.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kudryavtseva</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Кудрявцева</surname><given-names>Л. В.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mikhaleva</surname><given-names>L. M.</given-names></name><name xml:lang="ru"><surname>Михалева</surname><given-names>Л. М.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Babichenko</surname><given-names>I. I.</given-names></name><name xml:lang="ru"><surname>Бабиченко</surname><given-names>И. И.</given-names></name></name-alternatives><email>kgosha@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Peoples’ Friendship University of Russia (RUDN University)</institution></aff><aff><institution xml:lang="ru">Российский университет дружбы народов</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research institute of human morphology</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт морфологии человека</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2019</year></pub-date><volume>23</volume><issue>4</issue><issue-title xml:lang="en">VOL 23, NO4 (2019)</issue-title><issue-title xml:lang="ru">ТОМ 23, №4 (2019)</issue-title><fpage>364</fpage><lpage>372</lpage><history><date date-type="received" iso-8601-date="2020-02-03"><day>03</day><month>02</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Kudryavtsev G.Y., Kudryavtseva L.V., Mikhaleva L.M., Babichenko I.I.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, Кудрявцев Г.Ю., Кудрявцева Л.В., Михалева Л.М., Бабиченко И.И.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Kudryavtsev G.Y., Kudryavtseva L.V., Mikhaleva L.M., Babichenko I.I.</copyright-holder><copyright-holder xml:lang="ru">Кудрявцев Г.Ю., Кудрявцева Л.В., Михалева Л.М., Бабиченко И.И.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.rudn.ru/medicine/article/view/22796">https://journals.rudn.ru/medicine/article/view/22796</self-uri><abstract xml:lang="en"><p>Prostate cancer is one of the leading causes of men death in developed countries. Modern diagnostic methods, including a puncture biopsy of the prostate gland, make it possible to verify oncology in the early stages, however, routine studies do not always allow to predict the course of the disease and outcome. The aim of our study was to analyze the clinical, morphological and immunohistochemical features of the proliferative activity of adenocarcinoma cells using the Ki-67 marker, to compare the degree of proliferative activity in tumors of various degrees of malignancy (according to Gleason’s classification), as well as to compare this indicator with the clinical stage of the disease, the level of prostate-specific antigen in the blood, the size of the prostate gland. Materials and Methods: On the basis of the City Clinical Hospital No. 31 and the Veteran Hospital No. 2, paraffin blocks with material obtained as a result of prostate biopsy, transurethral resection, and radical prostatectomy were selected. A morphological and immunohistochemical study of the material with the Ki-67 marker and a quantitative assessment of the degree of proliferative activity were carried out. Data were analyzed using the STATISTICA 10.0 program using estimates of the normality of the data distribution according to the Shapiro-Wilk W-test, the significance of differences was estimated using the Mann-Whitney U-test, and correlation relationships using Spearman’s correlation coefficient. Results: Statistically significant differences in the degree of proliferative activity in groups differing in the degree of differentiation were revealed. A statistically significant direct correlation of moderate severity was revealed when comparing proliferative activity with the degree of differentiation according to the Gleason system (rs = 0.523) and the clinical stage of the disease (rs = 0.646). No statistically significant correlation was found between indicators such as prostate-specific antigen level, age, prostate volume, and proliferative activity index. Conclusion: taking into account the proliferative activity index in addition to clinical and morphological studies helps to diagnose and subsequently predict the course of prostate cancer.</p></abstract><trans-abstract xml:lang="ru"><p>Актуальность. Рак предстательной железы является одной из ведущих причин смерти мужского населения от онкологических заболеваний в развитых странах. Современные методы диагностики, в том числе пункционная биопсия предстательной железы, позволяют верифицировать онкологию на ранних стадиях, однако рутинные исследования не всегда позволяют спрогнозировать течение и исход заболевания. Цель: провести анализ клинико-морфологических и иммуногистохимических особенностей клеток аденокарциномы, с использованием маркера Ki-67, сопоставление степени пролиферативной активности в опухолях различной степени злокачественности (по классификации Глисона), а также сравнение данного показателя с клинической стадией заболевания, уровнем простатспецифического антигена в крови, объемом предстательной железы. Материалы и методы: На базе ГБУЗ ДЗМ «Городская клиническая больница № 31» и «Госпиталь для ветеранов воин № 2» были отобраны парафиновые блоки с материалом, полученным в результате биопсии предстательной железы, трансуретральной резекции и радикальной простатэктомии. Проведено морфологическое и иммуногистохимическое исследование материала с маркером Ki-67. Полученные данные проанализированы при помощи программы STATISTICA 10.0 с использованием оценки нормальности распределения данных по W-критерию Шапиро-Уилка, достоверность различий оценивалась с помощью U-критерия Манна-Уитни, а корреляционные взаимоотношения с помощью коэффициента корреляции Спирмена. Результаты: Выявлены статистически значимые отличия пролиферативной активности в группах злокачественной опухоли с разной степенью дифференцировки. Статистически значимая прямая корреляция умеренной выраженности была выявлена при сопоставлении пролиферативной активности со степенью дифференцировки по системе Глисона (rs = 0,523) и клинической стадией заболевания (rs = 0,646). Между такими показателями, как уровень простатспецифического антигена, возраст, объем предстательной железы и индексом пролиферативной активности статистически значимых корреляционных зависимостей обнаружено не было. Заключение: учет индекса пролиферативной активности в дополнение к клинико-морфологическому исследованию способствует диагностике и последующему прогнозированию течения рака предстательной железы.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Ki-67</kwd><kwd>prostate adenocarcinoma</kwd><kwd>prostate-specific antigen</kwd><kwd>Ki-67</kwd><kwd>proliferation</kwd><kwd>Gleason index</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аденокарцинома предстательной железы</kwd><kwd>простатспецифический антиген</kwd><kwd>пролиферация</kwd><kwd>индекс Глисона</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Cooperberg M, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314(1): 80-82.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Matoso A, Epstein JI. Grading of prostate cancer: Past, present, and future. Curr Urol Rep. 2016;17: 576-8.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Gordetsky J, Epstein J. Grading of prostatic adenocarcinoma: current state and prognostic implications. Diagn Pathol. 2016;11: 1-8.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Léon P, Cancel-Tassin G, Drouin S. Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy. World J Urol. 2018;36: 1495-1500.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Bratt O, Folkvaljon Y, Hjalm Eriksson M, Akre O, Carlsson S, Drevin L. et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 2015;68(1): 53-58.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Babichenko II, Andriukhin MI, Pulbere S, Loktev A. Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma. Int J Clin Exp Pathol. 2014;7(12): 9090-8.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Berlin A, Castro-Mesta JF, Rodriguez-Romo L, Hernandez-Barajas D, González-Guerrero JF, Rodríguez-Fernández IA et al. Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis. Urol Oncol. 2017;35(8): 499-506.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>López IH, Parada D, Gallardo P, Gascón M, Besora A et al. Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy. Rep Pract Oncol Radiother. 2017;22(3): 251-7.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Boladeras A, Martinez E, Ferrer F. Localized prostate cancer treated with eternal beam radiation therapy: long-term outcome at a European comprehensive cancer centre. Rep Pract Oncol Radiother. 2016;21(3): 181-7.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Richards-Taylor S, Ewings SM, Jaynes E, Tilley C, Ellis SG, Armstrong T. et al. The assessment of Ki-67 as a prognostic marker in neuroendocrine tumors: a systematic review and meta-analysis. J Clin Pathol. 2016;69: 612-8.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE et al. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol. 2014;25: 1551-7.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Cserni G, Voros A, Liepniece-Karele I, Bianchi S, Vezzosi V. et al. Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values. Breast. 2014;23: 259-63.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Amin MB, Edge SB, Greene FL. AJCC Cancer Staging Manual. 8th ed. New York: Springer International Publishing; 2017. 451 p.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Epstein JI, Egevad L, Amin MB et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference of Gleason Grading of Prostatic Carcinoma. Am. J. Surg. Pathol. 2016, 40: 244-52.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Gevorkyan AR, Avakyan AYu, Efremov EA, Simakov VV. Correlation between Gleason score and PSA level. Experimental and Clinical Urology. 2014;3: 37-9.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kammerer-Jacquet SF, Ahmad A, Møller H, Sandu H, Scardino P, Soosay G et al. Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. Mod Pathol. 2019;32: 1303-9. doi: 10.1038/s41379-019-0268-y</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lobo J, Rodrigues Â, Antunes L, Graça I, Ramalho-Carvalho J, Vieira FQ et al. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer. Urol Oncol. 2018;36(4): 161.e7-161.e17. doi.org/10.1016/j.urolonc.2017.10.028</mixed-citation></ref></ref-list></back></article>
